drugset / Trial / NCT00651560
Vytorin As Strategy To Reduce Dislipidemia In Adults (0653A-148)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is intended to allow physicians to check the superior clinical efficacy of Vytorin compared to atorvastatin, as the most adequate therapy using the ATP-III goals achievement and cardiovascular risk reduction in adult patients with dislipidemia.
Timeline
- Start
- 2005-11-01
- Primary completion
- 2005-12-23
- Completion
- 2005-12-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ezetimibe | Unknown | 10 mg | — |
| Subject | Simvastatin | Small molecule | 20 mg | — |